Contemporary Targeted Therapies in Rheumatology

Josef S. Smolen, Peter E. Lipsky, Josef S. Smolen, Peter E. Lipsky

• Publisher: CRC Press
• Year: 2007
• Print ISBN:
  9781841844848
• eBook ISBN:
  9781135174637
• Topic: Medicine
• Subtopic: Immunology

Targeted therapies of rheumatic diseases have become a reality and have completely changed patient care as well as patient expectations. Initial success with therapies aimed at blocking TNF and IL-1 has stimulated the development of additional targeted approaches focused on other cytokines as well as specific cells and pathways involved in the path

Table of contents

• Cover
• Half Title
• Title Page
• Copyright Page
• Table of Contents
• Contributors
• 1 T cells   overview   update
• 2 Pathways of T-cell costimulation
• 3 Regulatory T cells
• 4 B-cell antigen receptor signaling and autoimmunity
• 5 Macrophages in rheumatoid arthritis
• 6 Dendritic cells
• 7 Osteoclasts
• 8 Cell contact dependence of inflammatory events
• 9 Toll-like receptors: possible targets for novel treatments for rheumatoid arthritis
• 10 Cadherin-11 mediates synovial lining organization: a new therapeutic targetin inflammatory arthritis
• 11 TNF-a
• 12 Update on interleukin-6
• 13 Interleukin-13
• 14 Biology of interleukin-15
• 15 Interleukin-17: a new target in arthritis
• 16 The role of interleukin-18 in inflammation
• 17 Interleukin-21
• 16 The biology of human interleukin-32
• 19 The interferons
• 20 Osteoprotegerin
• 21 Update: inflammatory, angiogenic, and homeostatic chemokines and their receptors
• 22 New developments in NF-kB
• 23 Roles of the JAK-STAT signaling pathways in rheumatoid arthritis
• 24 Suppressor of cytokine signaling (SOCS) proteins as therapeutic targets inrheumatoid arthritis
• 25 Wnt signaling for targeted therapies in rheumatology
• 26 Inflammatory mediators: update on cyclooxygenases andprostaglandin synthases
• 27 Complement and pregnancy loss
• 28 Matrix metalloproteinases
• 29 MMPs and ADAMs as targets for therapies in arthritis
• 30 Update on proinflammatory cytokine blockade in rheumatoid arthritis
• 31 Targeting interleukin-1 in rheumatic diseases
• 32 Update on targeted therapy in psoriatic arthritis
• 33 Spondyloarthritides
• 34 Early Arthritis
• 35 Juvenile arthritis
• 36 Update   systemic lupus erythematosus
• 37 Vasculitis
• 38 Myositis
• 39 TNF blockade in orphan rheumatic diseases
• 40 Overview of the safety of TNF inhibitors
• 41 Anti-CD20 to further targeted therapies in rheumatology
• 42 Targeting B-lymphocyte stimulator (BLyS) in immune-based rheumaticdiseases: a therapeutic promisewaiting to be fulfilled
• 43 Anti-CD3 antibody   a history of successful immune interventions
• 44 Alefacept
• 45 Clinical targeting of interleukin-15
• 46 Clinical prospects of MAPK inhibitors
• 47 Clinical prospects of NF-kB inhibitors to further targeted therapies in rheumatology
• 48 Outcomes assessment in rheumatic disease
• Index